Elba Raimúndez

Elba Raimúndez

Auto-generated profile, based on publicly available information

Elba Raimúndez

Sanofi R&D, Translational Medicine Unit, Quantitative Pharmacology, Development Pharmacometrics Frankfurt Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
LSLeonard Schmiester
Leonard Schmiester
YSYannik Schälte
Yannik Schälte
FBFrank T Bergmann
Frank T Bergmann
TCTacio Camba
Tacio Camba
EDErika Dudkin
Erika Dudkin
DWDaniel Weindl
Daniel Weindl
Reproducibility and reusability of the results of data-based modeling studies are essential. Yet, there has been—so far—no broadly supported format for the specification of parameter estimation problems in systems biology. Here, we introduce PEtab, a format which facilitates the specification of parameter estimation problems using Systems Biology Markup Language (SBML) models and a set of tab-separated value files describing the observation model and experimental data as well as parameters to be estimated. We already implemented PEtab support into eight well-established model simulation and parameter estimation toolboxes with hundreds of users in total. We provide a Python library for validation and modification of a PEtab problem and currently 20 example parameter estimation problems based on recent studies.

1 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
IHIvonne Haffner
Ivonne Haffner
KSKatrin Schierle
Katrin Schierle
ERElba Raimúndez
Elba Raimúndez
BGBirgitta Geier
Birgitta Geier
DMDieter Maier
Dieter Maier
FLFlorian Lordick
Florian Lordick
PURPOSE: Trastuzumab is the only approved targeted drug for first-line treatment of human epidermal growth factor receptor 2–positive (HER2+) metastatic gastric cancer (mGC). However, not all patients respond and most eventually progress. The multicenter VARIANZ study aimed to investigate the background of response and resistance to trastuzumab in mGC. METHODS: Patients receiving medical treatment for mGC were prospectively recruited in 35 German sites and followed for up to 48 months. HER2 status was assessed centrally by immunohistochemistry and chromogenic in situ hybridization. In addition, HER2 gene expression was assessed using qPCR. RESULTS: Five hundred forty-eight patients were enrolled, and 77 had HER2+ mGC by central assessment (14.1%). A high deviation rate of 22.7% between central and local test results was seen. Patients who received trastuzumab for centrally confirmed HER2+ mGC (central HER2+/local HER2+) lived significantly longer as compared with patients who received trastuzumab for local HER2+ but central HER2− mGC (20.5 months, n = 60 v 10.9 months, n = 65; hazard ratio, 0.42; 95% CI, 8.2 to 14.4; P < .001). In the centrally confirmed cohort, significantly more tumor cells stained HER2+ than in the unconfirmed cohort, and the HER2 amplification ratio was significantly higher. A minimum of 40% HER2+ tumor cells and a HER2 amplification ratio of ≥ 3.0 were calculated as optimized thresholds for predicting benefit from trastuzumab. CONCLUSION: Significant discrepancies in HER2 assessment of mGC were found in tumor specimens with intermediate HER2 expression. Borderline HER2 positivity and heterogeneity of HER2 expression should be considered as resistance factors for HER2-targeting treatment of mGC. HER2 thresholds should be reconsidered. Detailed reports with quantification of HER2 expression and amplification levels may improve selection of patients for HER2-directed treatment.

8 January 2019 in Bioinformatics
Verified
Journal Article
Open access
HHHelge Hass
Helge Hass
CLCarolin Loos
Carolin Loos
ERElba Raimúndez-Álvarez
Elba Raimúndez-Álvarez
JTJens Timmer
Jens Timmer
JHJan Hasenauer
Jan Hasenauer
CKClemens Kreutz
Clemens Kreutz
Motivation: Dynamic models are used in systems biology to study and understand cellular processes like gene regulation or signal transduction. Frequently, ordinary differential equation (ODE) models are used to model the time and dose dependency of the abundances of molecular compounds as well as interactions and translocations. A multitude of computational approaches, e.g. for parameter estimation or uncertainty analysis have been developed within recent years. However, many of these approaches lack proper testing in application settings because a comprehensive set of benchmark problems is yet missing. Results: We present a collection of 20 benchmark problems in order to evaluate new and existing methodologies, where an ODE model with corresponding experimental data is referred to as problem. In addition to the equations of the dynamical system, the benchmark collection provides observation functions as well as assumptions about measurement noise distributions and parameters. The presented benchmark models comprise problems of different size, complexity and numerical demands. Important characteristics of the models and methodological requirements are summarized, estimated parameters are provided, and some example studies were performed for illustrating the capabilities of the presented benchmark collection. Availability and implementation: The models are provided in several standardized formats, including an easy-to-use human readable form and machine-readable SBML files. The data is provided as Excel sheets. All files are available at https://github.com/Benchmarking-Initiative/Benchmark-Models, including step-by-step explanations and MATLAB code to process and simulate the models. Supplementary information: Supplementary data are available at Bioinformatics online.

11 March 2023 in Epidemics
Verified
Journal Article
Open access
LCLorenzo Contento
Lorenzo Contento
NCNoemi Castelletti
Noemi Castelletti
ERElba Raimúndez
Elba Raimúndez
RGRonan Le Gleut
Ronan Le Gleut
YSYannik Schälte
Yannik Schälte
JHJan Hasenauer
Jan Hasenauer
Mathematical models have been widely used during the ongoing SARS-CoV-2 pandemic for data interpretation, forecasting, and policy making. However, most models are based on officially reported case numbers, which depend on test availability and test strategies. The time dependence of these factors renders interpretation difficult and might even result in estimation biases. Here, we present a computational modelling framework that allows for the integration of reported case numbers with seroprevalence estimates obtained from representative population cohorts. To account for the time dependence of infection and testing rates, we embed flexible splines in an epidemiological model. The parameters of these splines are estimated, along with the other parameters, from the available data using a Bayesian approach. The application of this approach to the official case numbers reported for Munich (Germany) and the seroprevalence reported by the prospective COVID-19 Cohort Munich (KoCo19) provides first estimates for the time dependence of the under-reporting factor. Furthermore, we estimate how the effectiveness of non-pharmaceutical interventions and of the testing strategy evolves over time. Overall, our results show that the integration of temporally highly resolved and representative data is beneficial for accurate epidemiological analyses.

1 March 2021 in Epidemics
Verified
Journal Article
Open access
ERElba Raimúndez
Elba Raimúndez
EDErika Dudkin
Erika Dudkin
JVJakob Vanhoefer
Jakob Vanhoefer
EAEmad Alamoudi
Emad Alamoudi
SMSimon Merkt
Simon Merkt
JHJan Hasenauer
Jan Hasenauer
Epidemiological models are widely used to analyze the spread of diseases such as the global COVID-19 pandemic caused by SARS-CoV-2. However, all models are based on simplifying assumptions and often on sparse data. This limits the reliability of parameter estimates and predictions.

1 January 2019 in IFAC-PapersOnLine
Verified
Journal Article
Open access
AVAlejandro F. Villaverde
Alejandro F. Villaverde
ERElba Raimúndez
Elba Raimúndez
JHJan Hasenauer
Jan Hasenauer
JBJulio R. Banga
Julio R. Banga